{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-024697","form_type":"8-K","ticker":"SIGA","cik":"0001010086","company_name":"SIGA TECHNOLOGIES INC","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.861643+00:00","generated_at":"2026-06-02T15:19:43.945112+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SIGA Q1 2024: product sales $23.9M, net income $10.3M, $0.60 special dividend","bullets":["Product sales $23.9M vs $5.7M YoY; total revenues $25.4M vs $8.3M.","Operating income $11.3M vs loss $2.1M YoY; net income $10.3M vs loss $0.9M; diluted EPS $0.14 vs ($0.01).","Partner Japan Biotechno Pharma filed NDA for tecovirimat in Japan for smallpox, mpox, etc. on April 11, 2024.","Amendment to Meridian agreement: SIGA takes over international promotion of oral TPOXX effective June 1, 2024.","Special cash dividend of $0.60 per share declared March 12, paid April 11, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-024697","json":"https://secwatch.observer/filing/0001140361-24-024697.json","markdown":"https://secwatch.observer/filing/0001140361-24-024697.md","text":"https://secwatch.observer/filing/0001140361-24-024697.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1010086/000114036124024697/0001140361-24-024697-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1010086/000114036124024697/ef20028413_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T15:19:43.945112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8fd527a1582347d69177cd1540c5b5b3d179128f","claim":"SIGA TECHNOLOGIES INC reported three months ended March 31, 2024 results: revenue $ 25.4, net income $ 10.3, EPS $ 0.14.","evidence_excerpt":"Summary Financial Results ($ in millions, except per share amounts) Three Months Ended March 31 2024 2023 Product sales (1) $ 23.9 $ 5.7 Total revenues $ 25.4 $ 8.3 Operating income (loss) (2) $ 11.3 $ (2.1 ) Income (loss) before income taxes (2) $ 13.2 $ (1.2 ) Net income (loss) $ 10.3 $ (0.9 ) Diluted income (loss) per share $ 0.14 $ (0.01 )","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1010086/000114036124024697/0001140361-24-024697-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2024"},{"label":"Revenue","value":"$ 25.4"},{"label":"Net income","value":"$ 10.3"},{"label":"EPS","value":"$ 0.14"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}